Gilead has joined London-based cell therapy company Cell Medica as CEO after moving from the Chris Nowers-owned Kite Pharma where he was European head. He replaces Cell Medica founder Gregg Sando. The company has raised more than $130m to build its portfolio of CAR-T and TCR therapies which are still under development. It has yet to file for approval, but said Nowers had considerable experience of commercialising oncology programs in particular with Bristol-Myers’ checkpoint inhibitors Opdivo and Yervoy.
Chris Nowers has joined London-based cell therapy company Cell Medica as CEO after moving from the Gilead-owned Kite Pharma where he was European head. He replaces Cell Medica founder Gregg Sando. The company has raised more than $130m to build its portfolio of CAR-T and TCR therapies which are still under development. It has yet to file for approval, but said Nowers had considerable experience of commercialising oncology programs in particular with Bristol-Myers’ checkpoint inhibitors Opdivo and Yervoy.